Chuangyebang was informed that recently, Ruijian Bio, a company focusing on “First-in-class” and “Best-in-class” neurological and psychiatric drug research and development, completed an angel round of financing. Zijingang Capital completed the financing exclusively, and the new funds will be used for pipeline research and development and enterprise operations.
Ruijian’s first product focuses on medication for severe pain. Taking cancer pain as an example, about half of cancer patients in my country fail to effectively control cancer pain, and 30% of patients do not get effective relief from severe pain before their death; existing opioids are resistant to drugs, serious side effects, and strict regulations. In the past 20 years, no analgesic drugs with new targets and new mechanisms have been launched, all of which are molecular or dosage form improvements of existing drugs.
The follow-up pipeline layout also includes indications such as resistant depression, anti-drug addiction, and post-traumatic stress disorder (PTSD). Among them, there are more than 100 million patients with resistant depression in the world and more than 20 million in China. The development of psychotropic drugs is difficult, and most of the new psychotropic drug targets approved in recent years are the same as the prototype drug targets in the 1960s.
The core team members come from well-known domestic and foreign institutes and CNS drug R&D companies, covering all aspects of drug preclinical development. The founder was an assistant professor at the Department of Psychiatry at the University of Toronto, Canada and a researcher at the Center for Addiction and Mental Health. He has been deeply involved in the basic research of CNS drugs for many years. He has rich practical experience in the basic mechanism of the nervous system and early drug discovery, and has many cooperation with CNS new drug research and development companies. .
The company has three technology platforms including “Protein-Protein Interaction Analysis Platform”, “Peptide Penetrating Peptide/PDC Platform”, and “Neural Drug High-throughput Screening Platform”, which involve the core difficulties of CNS drug research and development, and have the ability to continuously launch new pipelines , and has the ability to carry out CRO services in exchange for cash flow.
The first pipeline is a non-opioid powerful analgesic that can penetrate the blood-brain barrier. The effectiveness, convenience and accessibility of the drug will be greatly improved. It is expected to become a major clinical breakthrough, and the risk of finished drugs is relatively low. The company’s follow-up pipelines include resistant depression, addiction, PTSD, etc., all of which are based on new targets; currently resistant depression, addiction relapse, PTSD and other drugs are in urgent need of safe and effective targeted treatment.
Regarding this financing, Zijingang Capital said: Based on the above core advantages, Zijingang Capital decided to become the first institutional investor of Ruijian Bio, to help Ruijian Bio set sail, and to realize major breakthroughs in therapeutic drugs in the mental and neurological fields as soon as possible, benefiting the patient.
media coverage
A new start-up state in the investment world
Related events
- “Ruijian Bio” completed the angel round of financing, and Zijingang Capital invested exclusively2022-07-20
- “Xinyue Bio” announced the completion of tens of millions of yuan in Pre-A round financing2022-07-08
- Development and Reform Commission: Further increase support for the listing of biological enterprises in the domestic capital market2022-05-10
- Xianweida completed 450 million yuan in Series C financing, led by IDG Capital2021-10-12
- Highgrade Biotech completed USD 75 million in Series D financing to accelerate the advancement of innovative pipeline varieties2021-06-15
This article is reprinted from: https://readhub.cn/topic/8hNBvzgm253
This site is for inclusion only, and the copyright belongs to the original author.